Upstream Bio, Inc.

Upstream Bio, Inc. is a U.S.-based clinical-stage biotechnology company developing antibody-based treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. Its lead product candidate, verekitug, is being developed for asthma and other immune-mediated respiratory conditions through preclinical and clinical programs.

−5 612,2 %

−5 026,0 %

+20,4 %

26.15

26.15

— Upstream Bio, Inc.
%
Verekitug clinical development100% Research and clinical development of verekitug across respiratory and inflammatory indications.
Collaboration revenue0% Revenue recognized from partnered development work under the Maruho License Agreement.

Upstream Bio does not sell approved commercial products; its current counterparties are clinical research...

  • Clinical development partnersprimary

    CROs, CMOs, and investigator sites that execute trials, manufacture material, and support development operations.

  • Licensing and collaboration partnersprimary

    Partners such as Maruho that fund or participate in development work and generate collaboration revenue.

  • Future specialty prescriberssecondary

    Pulmonologists, allergists, and other physicians who would prescribe verekitug if approved.

  • Future payorssecondary

    Commercial and government payors that would determine reimbursement access after approval.

The company is headquartered in the United States and conducts its clinical and corporate activities from there...

  • •United States is the core operating base and primary market
  • •Clinical development and regulatory oversight are centered in the U.S.
  • •Healthcare laws and payor rules also matter in other jurisdictions
  • •Third-party manufacturing includes Hong Kong-based supply exposure
  • •Future commercialization could expand into ex-U.S. markets

Upstream Bio’s strategy is to advance verekitug through clinical trials across multiple respiratory indications and...

01
Advance verekitug through clinical developmentshort-term

Clinical data is the main value driver for a single-asset biotech company.

02
Broaden the indication set for verekitugmedium-term

Multiple respiratory indications can expand the addressable market and reduce single-indication risk.

03
Maintain external manufacturing and collaboration capacityshort-term

The company depends on third parties for APIs, drug product, and partnered development work.

Upstream Bio faces the typical risks of a clinical-stage biotech: limited operating history, dependence on capital...

critical

Clinical and regulatory failure of verekitug

The company’s value is concentrated in a small number of development programs, so setbacks can materially impair prospects.

Scope
verekitug and related respiratory indications
Materiality
high
high

Need for additional capital

The company has no product sales and expects to fund operations through external financing until commercialization or partnering.

Scope
corporate funding and development continuity
Materiality
high
high

Third-party manufacturing dependence

APIs and final drug product are sourced from external manufacturers, which can affect supply, quality, and timelines.

Scope
WuXi and other CMO relationships
Materiality
high
high

Competitive pressure in respiratory biologics

Larger biopharma companies may obtain approvals, exclusivity, or market access sooner.

Scope
asthma, COPD, and CRSwNP markets
Materiality
high
medium

Healthcare law and payor compliance

Future commercialization and collaboration arrangements must comply with fraud, abuse, and privacy rules.

Scope
U.S. and international healthcare regulation
Materiality
medium
Collaboration revenue recognition
Affects reported revenue timing and comparability across quarters
Research and development cost capitalization versus expense
Drives quarter-to-quarter operating loss volatility
Prepayments and cancellation terms
Affects balance sheet assets and near-term cash outflows
Stock-based compensation
Impacts R&D and G&A expense presentation

Inmune Bio, Inc.

INMB · Biological Products, (No Diagnostic Substances)

Evommune, Inc.

EVMN · Pharmaceutical Preparations

Climb Bio, Inc.

CLYM · Pharmaceutical Preparations

Spero Therapeutics, Inc.

SPRO · Pharmaceutical Preparations

Generation Bio Co.

Pharmaceutical Preparations

Gossamer Bio, Inc.

GOSS · Pharmaceutical Preparations

: 29/04/2026